Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose BCNU/Melphalan + Stem Cell Transplant + DCEP/Taxol/Cisplatin in Poor Prognosis NHL and CLL
NCT00003402Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 1999
- Primary completion
- Dec 2002
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine, melphalan, cyclophosphamide, dexamethasone, etoposide in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), sponsored by University of Maryland, Baltimore. Started Jan 1999; status: completed.
02
Drugs
carmustinemelphalancyclophosphamidedexamethasoneetoposide
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00003402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003402.